Information importante : Les informations contenues dans cet article ne constituent pas un avis mdical et ne remplacent pas une consultation avec un professionnel de sant qualifi
Pathogenesis of genital tract disease due to Chlamydia trachomatis
Disclosures: Dominique Larrey: SANOFI: Consultant, Dominique Larrey: Sanofi: Employee, Sanofi: Stock - publicly traded company, Claire Brulle-Wohlhueter: SANOFI: Stock options, Myriam Benamor: Nothing to Disclose, Jeffrey Chavin: Sanofi: Employee, Neda Razaz: Nothing to Disclose, Raphael Bejuit: Nothing to Disclose, Julien Dauriat: Sanofi: Consultant, Bayer: Consultant, Novartis: Consultant, Romane Pan: Sanofi: Consultant, Sanofi: Consultant, Servier: Consultant, Abbvie: Consultant, Neurochlore: Consultant, Thophile Reppelin: Nothing to Disclose, Sam Ekhtiari: Sanofi: Consultant, Nicolas Wagner: Sanofi: Consultant, Sanofi: Consultant, Fred Lublin: Sanofi: speaker, Avotres: stock options, Neuralight: stock options, Lapix therapeutic: stock options, Entelexo: stock options, novartis: source of funding for research, biogen: source of funding for research, Sanofi: source of funding for research, brainstorm cell therapeutics: source of funding for research, biogen: Consultant, EMD Serono: Consulting Agreements/Advisory Boards, Sanofi: Consulting Agreements/Advisory Boards, Biogen: Consulting Agreements/Advisory Boards, Novartis: Consulting Agreements/Advisory Boards, Janssen: Consulting Agreements/Advisory Boards, Roche/Genetech: Consulting Agreements/Advisory Boards, Horizen therapeutics/Amgen: Consulting Agreements/Advisory Boards, brainstorm cell therapeutics: Consulting Agreements/Advisory Boards, Mapi Pharma: Consulting Agreements/Advisory Boards, Mylan/Viatris: Consulting Agreements/Advisory Boards, Immunic: Consulting Agreements/Advisory Boards, Avotres: Consulting Agreements/Advisory Boards, Neuralight: Consulting Agreements/Advisory Boards, Neurogene: Consulting Agreements/Advisory Boards, Labcorp: Consulting Agreements/Advisory Boards, Entelexo biotherapeutics: Consulting Agreements/Advisory Boards, Setpoint medical: Consulting Agreements/Advisory Boards, Hexal/Sandoz: Consulting Agreements/Advisory Boards, Baim Institute: Consulting Agreements/Advisory Boards, Sudo biosciences: Consulting Agreements/Advisory Boards, Lapix therapeutics: Consulting Agreements/Advisory Boards, Biohaven Pharmaceuticals: Consulting Agreements/Advisory Boards, Abata therapeutics: Consulting Agreements/Advisory Boards, Cognito Therapeutics: Consulting Agreements/Advisory Boards, ImmPACT Bio: Consulting Agreements/Advisory Boards 1247 TRANSDILI: A DEEP TRANSFER LEARNING BASED PREDICTION FOR DRUG-INDUCED LIVER INJURY THROUGH LEVERAGING MOLECULAR STRUCTURE IMAGES Yue Li 1 Bingyan Liu 2 Yuanchun Guo 2 Jinyan Deng 1 Yi Guo 1 Hongbo Du 1 , 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, 2 Beijing University of Posts and Telecommunication Background: Drug- induced liver injury (DILI) poses a global threat to acute liver failure
US$ 38.00 Shipping to United States Free Standard Shipping with any US$ 35 purchase (10 - 14 business days) Returns and Exchanges Features Benefits: How to use: 1
Neuroinflammation Induces Neurodegeneration
Supports respiratory health: It is often used in patients with chronic conditions (e.g., asthma) for immune support
